questionText: To ask the Secretary of State for Health and Social Care, whether she is working with her international counterparts to tackle supply issues relating to (a) semaglutide and (b) other glucagon-like peptide-1 receptor agonists licensed for treating patients
answerText: The Department has worked intensively with industry to seek commitments from them to address issues with the supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, to expedite deliveries and boost supplies. As a result, th...
heading: Diabetes: Drugs